Clene's ALS drug shows reduction in disease indicator in mid-stage trial
15/06/2023 21:44
June 15 (Reuters) - Clene Inc CLNN.O said on Thursday its experimental drug to treat amyotrophic lateral sclerosis showed reduction in levels of a protein that indicates neurodegeneration in patients in a mid-stage trial. (Reporting by Raghav Mahobe in Bengaluru; Editing by Krishna Chandra ELuri) ((Raghav.Mahobe@thomsonreuters.com;))
Recent news on Clene
See all newsClene Inc reports results for the quarter ended June 30 - Earnings Summary
Clene Q2 net loss widens on higher other expenses
Clene Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Clene Inc - Enters Second Amendment To Senior Secured Convertible Notes - SEC Filing
Clene Q1 loss widens on warrant liability issuance costs